Looking for the Keys Under the Streetlight
An old joke about research tells of a man searching for his lost keys under a streetlight. A policeman asks if that’s where he dropped them. The man replies, “No, but the light is better here.”
What we learn from research depends on where we choose to look. Those who dismiss natural therapies as “unscientific” often overlook a basic truth: research tends to follow funding, and funding tends to follow profit. That doesn’t make all research invalid, but it does shape what questions get asked and which answers become “accepted.”
A study from Wake Forest University School of Medicine, published in BMC Complementary and Alternative Medicine (2008), examined pharmaceutical advertising in medical journals and compared it with coverage of dietary supplements and natural therapies. Journals with more pharmaceutical advertising were less likely to publish articles about supplements, and when they did, the tone tended to be more negative. Advertising revenue doesn’t prove bias — but it creates a financial environment where certain topics receive more attention and others less.
This pattern has consequences. Prescription drug spending rose dramatically in the late 1990s and early 2000s, and it has continued climbing since. As spending grew, so did the number of Americans taking medications. Surveys have shown that a large portion of the population takes at least one prescription drug, and a significant minority takes multiple drugs simultaneously. Direct-to-consumer advertising, which expanded rapidly in the late 1990s, helped turn medications into household brands.
Health care is often described as a purely scientific and altruistic endeavor. For many practitioners, it is. But health care is also a major industry, and industry follows incentives. Patentable drugs receive large trials, marketing campaigns, and journal visibility. Nutrients and physiologic support strategies — which cannot be patented in the same way — rarely receive that level of attention, even when there is physiologic rationale and clinical experience behind them.
This imbalance affects how disease is framed. Heart disease becomes a problem of cholesterol numbers, rather than mitochondrial function, oxidative stress, nutrient depletion, inflammation, and vascular health. Statins, which are patentable, become central. Natural substances like CoQ10, carnitine, magnesium, and mixed tocopherols remain peripheral — not necessarily because they lack value, but because they do not fit the dominant research and business model.
This reflects a system in which marketing, funding, and publication channels overlap. When financial incentives shape what gets studied and promoted, the result can be a medical culture that manages chronic disease with escalating layers of medication while paying less attention to foundational physiology.
Adverse drug reactions are a significant cause of hospitalizations and deaths each year, even when medications are used as directed. This doesn’t mean drugs have no role; many are lifesaving. It does mean that equating “well marketed and heavily studied” with “most important” can lead us to confuse commercial momentum with scientific priority.
If we want a health care system that truly follows science, we must be willing to look beyond the streetlight — and ask whether we are studying what is easiest to fund, or what is most fundamental to human health.
